201 related articles for article (PubMed ID: 31358114)
1. R-propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma.
Overman J; Fontaine F; Wylie-Sears J; Moustaqil M; Huang L; Meurer M; Chiang IK; Lesieur E; Patel J; Zuegg J; Pasquier E; Sierecki E; Gambin Y; Hamdan M; Khosrotehrani K; Andelfinger G; Bischoff J; Francois M
Elife; 2019 Jul; 8():. PubMed ID: 31358114
[TBL] [Abstract][Full Text] [Related]
2. A transcription factor is the target of propranolol treatment in infantile hemangioma.
Schrenk S; Boscolo E
J Clin Invest; 2022 Feb; 132(3):. PubMed ID: 35104803
[TBL] [Abstract][Full Text] [Related]
3. Non-beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma.
Seebauer CT; Graus MS; Huang L; McCann A; Wylie-Sears J; Fontaine F; Karnezis T; Zurakowski D; Staffa SJ; Meunier F; Mulliken JB; Bischoff J; Francois M
J Clin Invest; 2022 Feb; 132(3):. PubMed ID: 34874911
[TBL] [Abstract][Full Text] [Related]
4. Expanding the clinical spectrum of SOX18-related Hypotrichosis-lymphedema-telangiectasia-renal defect syndrome.
Dailey C; Oshodi RB; Boull C; Aggarwal A
Eur J Med Genet; 2022 Nov; 65(11):104607. PubMed ID: 36096470
[TBL] [Abstract][Full Text] [Related]
5. Hypotrichosis-lymphedema-telangiectasia-renal defect associated with a truncating mutation in the SOX18 gene.
Moalem S; Brouillard P; Kuypers D; Legius E; Harvey E; Taylor G; Francois M; Vikkula M; Chitayat D
Clin Genet; 2015 Apr; 87(4):378-82. PubMed ID: 24697860
[TBL] [Abstract][Full Text] [Related]
6. Further delineation of the SOX18-related Hypotrichosis, Lymphedema, Telangiectasia syndrome (HTLS).
Valenzuela I; Fernández-Alvarez P; Plaja A; Ariceta G; Sabaté-Rotés A; García-Arumí E; Vendrell T; Tizzano E
Eur J Med Genet; 2018 May; 61(5):269-272. PubMed ID: 29307792
[TBL] [Abstract][Full Text] [Related]
7. A novel autosomal dominant mutation in SOX18 resulting in a fatal case of hypotrichosis-lymphedema-telangiectasia syndrome.
Wangberg H; Wigby K; Jones MC
Am J Med Genet A; 2018 Dec; 176(12):2824-2828. PubMed ID: 30549413
[TBL] [Abstract][Full Text] [Related]
8. Hypotrichosis-lymphedema-telangiectasia syndrome: Report of ileal atresia associated with a SOX18 de novo pathogenic variant and review of the phenotypic spectrum.
Coulie R; Niyazov DM; Gambello MJ; Fastré E; Brouillard P; Vikkula M
Am J Med Genet A; 2021 Jul; 185(7):2153-2159. PubMed ID: 33851505
[TBL] [Abstract][Full Text] [Related]
9. A novel SOX18 mutation uncovered in Jordanian patient with hypotrichosis-lymphedema-telangiectasia syndrome by Whole Exome Sequencing.
Bastaki F; Mohamed M; Nair P; Saif F; Tawfiq N; Al-Ali MT; Brandau O; Hamzeh AR
Mol Cell Probes; 2016 Feb; 30(1):18-21. PubMed ID: 26631803
[TBL] [Abstract][Full Text] [Related]
10. Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia.
Irrthum A; Devriendt K; Chitayat D; Matthijs G; Glade C; Steijlen PM; Fryns JP; Van Steensel MA; Vikkula M
Am J Hum Genet; 2003 Jun; 72(6):1470-8. PubMed ID: 12740761
[TBL] [Abstract][Full Text] [Related]
11. Vascular defects in a mouse model of hypotrichosis-lymphedema-telangiectasia syndrome indicate a role for SOX18 in blood vessel maturation.
Downes M; François M; Ferguson C; Parton RG; Koopman P
Hum Mol Genet; 2009 Aug; 18(15):2839-50. PubMed ID: 19429912
[TBL] [Abstract][Full Text] [Related]
12. Aortic Dilatation Associated With a De Novo Mutation in the SOX18 Gene: Expanding the Clinical Spectrum of Hypotrichosis-Lymphedema-Telangiectasia Syndrome.
Wünnemann F; Kokta V; Leclerc S; Thibeault M; McCuaig C; Hatami A; Stheneur C; Grenier JC; Awadalla P; Mitchell GA; Andelfinger G; Preuss C
Can J Cardiol; 2016 Jan; 32(1):135.e1-7. PubMed ID: 26148450
[TBL] [Abstract][Full Text] [Related]
13. Role of Thrombospondin-1 and Nuclear Factor-κB Signaling Pathways in Antiangiogenesis of Infantile Hemangioma.
Xu W; Li S; Yu F; Zhang Y; Yang X; An W; Wang W; Sun C
Plast Reconstr Surg; 2018 Sep; 142(3):310e-321e. PubMed ID: 30148773
[TBL] [Abstract][Full Text] [Related]
14. Propranolol represses infantile hemangioma cell growth through the β2-adrenergic receptor in a HIF-1α-dependent manner.
Li P; Guo Z; Gao Y; Pan W
Oncol Rep; 2015 Jun; 33(6):3099-107. PubMed ID: 25872592
[TBL] [Abstract][Full Text] [Related]
15. Serum-level changes of vascular endothelial growth factor in children with infantile hemangioma after oral propranolol therapy.
Chen XD; Ma G; Huang JL; Chen H; Jin YB; Ye XX; Hu XJ; Lin XX
Pediatr Dermatol; 2013; 30(5):549-53. PubMed ID: 23909679
[TBL] [Abstract][Full Text] [Related]
16. Success in the use of oral propranolol in the treatment of infantile hemangioma in nasal tip - Report of two cases.
Costa MC; Andrade OGC; Pereira LC; Costa IMC
An Bras Dermatol; 2020; 95(2):207-209. PubMed ID: 32061465
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics and Pharmacodynamics of Oral Propranolol in Pediatric Patients With Infantile Hemangioma.
Takechi T; Kumokawa T; Kato R; Higuchi T; Kaneko T; Ieiri I
J Clin Pharmacol; 2018 Oct; 58(10):1361-1370. PubMed ID: 29746707
[TBL] [Abstract][Full Text] [Related]
18. Treatment of infantile hemangiomas with propranolol: clinical guidelines.
Szychta P; Stewart K; Anderson W
Plast Reconstr Surg; 2014 Apr; 133(4):852-862. PubMed ID: 24352207
[TBL] [Abstract][Full Text] [Related]
19. A dominant-negative SOX18 mutant disrupts multiple regulatory layers essential to transcription factor activity.
McCann AJ; Lou J; Moustaqil M; Graus MS; Blum A; Fontaine F; Liu H; Luu W; Rudolffi-Soto P; Koopman P; Sierecki E; Gambin Y; Meunier FA; Liu Z; Hinde E; Francois M
Nucleic Acids Res; 2021 Nov; 49(19):10931-10955. PubMed ID: 34570228
[TBL] [Abstract][Full Text] [Related]
20. A retrospective study of 2 or 3 mg/kg/day propranolol for infantile hemangioma.
Goto K; Ozeki M; Yasue S; Endo S; Fukao T
Pediatr Int; 2020 Jun; 62(6):751-753. PubMed ID: 32490577
[No Abstract] [Full Text] [Related]
[Next] [New Search]
